80 FR 193 pgs. 60400-60405 - Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016
Type: NOTICEVolume: 80Number: 193Pages: 60400 - 60405
Pages: 60400, 60401, 60402, 60403Docket number: [Docket No. DEA-420F]
FR document: [FR Doc. 2015-25373 Filed 10-5-15; 8:45 am]
Agency: Justice Department
Sub Agency: Drug Enforcement Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-420F]
Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016
AGENCY:
Drug Enforcement Administration, Department of Justice.
ACTION:
Final order.
SUMMARY:
This final order establishes the initial 2016 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.
DATES:
Effective October 6, 2015.
FOR FURTHER INFORMATION CONTACT:
John R. Scherbenske, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 598-6812.
SUPPLEMENTARY INFORMATION:
Legal Authority
[top] The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. Titles II and III are referred to as the "Controlled Substances Act" and the "Controlled Substances Import and Export Act," respectively, and are collectively referred to as the "Controlled Substances Act" or the "CSA" for the purpose of this action. 21
Section 306 of the Controlled Substances Act (CSA), 21 U.S.C. 826, requires the Attorney General to determine the total quantity and establish production quotas for each basic class of controlled substance in schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine to be manufactured each calendar year to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. This responsibility has been delegated to the Administrator of the DEA through 28 CFR 0.100(b).
Background
The 2016 aggregate production quotas and assessment of annual needs represent those quantities of schedule I and II controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine that may be manufactured in the United States in 2016 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do not include imports of controlled substances for use in industrial processes.
On July 17, 2015, a notice titled, "Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Proposed Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016" was published in the Federal Register . 80 FR 42540. This notice proposed the 2016 aggregate production quotas for each basic class of controlled substance listed in schedules I and II and the 2016 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. All interested persons were invited to comment on or object to the proposed aggregate production quotas and the proposed assessment of annual needs on or before August 17, 2015.
Comments Received
Twenty comments were received from four DEA-registered manufacturers within the published comment period regarding 17 different schedule I and II controlled substances. The DEA did not receive any comments regarding the proposed assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. Commenters stated that the proposed aggregate production quotas for [1-(5-fluoropentyl)-1 H -indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201), amphetamine (for sale), codeine (for sale), gamma hydroxybutric acid, levorphanol, marihuana, methylphenidate, N -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 H -indazole-3-carboxamide (ADB-PINACA), N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide (AB-FUBINACA), N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 H -indazole-3-carboxamide (AB-CHMINACA), N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1 H -indazole-3-carboxamide (AB-PINACA), N -(1-phenethylpiperidin-4-yl)- N -phenylacetamide (acetyl fentanyl), nabilone, oxymorphone (for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-1 H -indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-1 H -indole-3-carboxylate (PB-22) were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks.
Determination of 2016 Aggregate Production Quotas and Assessment of Annual Needs
In determining the 2016 aggregate production quotas and assessment of annual needs, the DEA has taken into consideration the above comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 1315.11, in accordance with 21 U.S.C. 826(a), and other relevant factors, including the 2015 manufacturing quotas, current 2015 sales and inventories, anticipated 2016 export requirements, industrial use, additional applications for 2016 quotas, as well as information on research and product development requirements. Based on this information, the DEA has determined that adjustments to the proposed aggregate production quotas for codeine (for sale), hydromorphone, marihuana, methylphenidate, and N -(1-phenethylpiperidin-4-yl)- N -phenylacetamide (acetyl fentanyl) are warranted. This final order reflects those adjustments.
Regarding [1-(5-fluoropentyl)-1 H -indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201), amphetamine (for sale), gamma hydroxybutric acid, levorphanol, N -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 H -indazole-3-carboxamide (ADB-PINACA), N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide (AB-FUBINACA), N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 H -indazole-3-carboxamide (AB-CHMINACA), N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1 H -indazole-3-carboxamide (AB-PINACA), nabilone, oxymorphone (for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-1 H -indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-1 H -indole-3-carboxylate (PB-22), the DEA has determined that the proposed aggregate production quotas are sufficient to provide for the 2016 estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. This final order establishes these aggregate production quotas at the same amounts as proposed.
[top] As described in the previously published notice proposing the 2016 aggregate production quotas and assessment of annual needs, the DEA has specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, the DEA has included in all established schedule II aggregate production quotas, and certain schedule I aggregate production quotas, an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The established aggregate production quotas will reflect these included amounts. This action will not affect the ability of
In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 1315.11, the Administrator hereby establishes the 2016 aggregate production quotas for the following schedule I and II controlled substances and the 2016 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:
[top]
| Basic class | Established 2016 quotas (g) |
|---|---|
| Schedule I | |
| (1-Pentyl-1 H -indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) | 25 |
| [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201) | 15 |
| [1-(5-Fluoro-pentyl)-1 H -indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) | 25 |
| 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) | 25 |
| 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) | 25 |
| 1-(1-Phenylcyclohexyl)pyrrolidine | 10 |
| 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) | 45 |
| 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) | 45 |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine | 15 |
| 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) | 45 |
| 1-Butyl-3-(1-naphthoyl)indole (JWH-073) | 45 |
| 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) | 45 |
| 1-Hexyl-3-(1-naphthoyl)indole (JWH-019) | 45 |
| 1-Methyl-4-phenyl-4-propionoxypiperidine | 2 |
| 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) | 45 |
| 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) | 45 |
| 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) | 45 |
| 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) | 45 |
| 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) | 45 |
| 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) | 45 |
| 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) | 45 |
| 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) | 30 |
| 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) | 30 |
| 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) | 30 |
| 2-(2,5-Dimethoxy-4- n -propylphenyl)ethanamine (2C-P) | 30 |
| 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) | 30 |
| 2-(4-Bromo-2,5-dimethoxyphenyl)- N -(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) | 25 |
| 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) | 30 |
| 2-(4-Chloro-2,5-dimethoxyphenyl)- N -(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) | 25 |
| 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) | 30 |
| 2-(4-Iodo-2,5-dimethoxyphenyl)- N -(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) | 15 |
| 2-(Methylamino)-1-phenylpentan-1-one (pentedrone) | 25 |
| 2,5-Dimethoxy-4-ethylamphetamine (DOET) | 25 |
| 2,5-Dimethoxy-4- n -propylthiophenethylamine | 25 |
| 2,5-Dimethoxyamphetamine | 25 |
| 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) | 30 |
| 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) | 30 |
| 3,4,5-Trimethoxyamphetamine | 25 |
| 3,4-Methylenedioxyamphetamine (MDA) | 55 |
| 3,4-Methylenedioxymethamphetamine (MDMA) | 50 |
| 3,4-Methylenedioxy- N -ethylamphetamine (MDEA) | 40 |
| 3,4-Methylenedioxy- N -methylcathinone (methylone) | 50 |
| 3,4-Methylenedioxypyrovalerone (MDPV) | 35 |
| 3-Fluoro- N -methylcathinone (3-FMC) | 25 |
| 3-Methylfentanyl | 2 |
| 3-Methylthiofentanyl | 2 |
| 4-Bromo-2,5-dimethoxyamphetamine (DOB) | 25 |
| 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) | 25 |
| 4-Fluoro- N -methylcathinone (4-FMC) | 25 |
| 4-Methoxyamphetamine | 150 |
| 4-Methyl-2,5-dimethoxyamphetamine (DOM) | 25 |
| 4-Methylaminorex | 25 |
| 4-Methyl- N -ethylcathinone (4-MEC) | 25 |
| 4-Methyl- N -methylcathinone (mephedrone) | 45 |
| 4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) | 25 |
| 5-(1,1-Dimethylheptyl)-2-[(1 R, 3 S )-3-hydroxycyclohexyl]-phenol | 68 |
| 5-(1,1-Dimethyloctyl)-2-[(1 R, 3 S )-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) | 53 |
| 5-Methoxy-3,4-methylenedioxyamphetamine | 25 |
| 5-Methoxy- N,N -diisopropyltryptamine | 25 |
| 5-Methoxy- N,N -dimethyltryptamine | 25 |
| Acetyl- alpha -methylfentanyl | 2 |
| Acetyldihydrocodeine | 2 |
| Acetylmethadol | 2 |
| Allylprodine | 2 |
| Alphacetylmethadol | 2 |
| alpha -Ethyltryptamine | 25 |
| Alphameprodine | 2 |
| Alphamethadol | 2 |
| alpha -Methylfentanyl | 2 |
| alpha -Methylthiofentanyl | 2 |
| alpha -Methyltryptamine (AMT) | 25 |
| alpha -Pyrrolidinobutiophenone (a-PBP) | 25 |
| alpha -Pyrrolidinopentiophenone (a-PVP) | 25 |
| Aminorex | 25 |
| Benzylmorphine | 2 |
| Betacetylmethadol | 2 |
| beta -Hydroxy-3-methylfentanyl | 2 |
| beta -Hydroxyfentanyl | 2 |
| Betameprodine | 2 |
| Betamethadol | 4 |
| Betaprodine | 2 |
| Bufotenine | 3 |
| Cathinone | 70 |
| Codeine methylbromide | 5 |
| Codeine- N -oxide | 305 |
| Desomorphine | 25 |
| Diethyltryptamine | 25 |
| Difenoxin | 11,000 |
| Dihydromorphine | 3,000,000 |
| Dimethyltryptamine | 35 |
| Dipipanone | 5 |
| Fenethylline | 5 |
| gamma -Hydroxybutyric acid | 70,250,000 |
| Heroin | 50 |
| Hydromorphinol | 2 |
| Hydroxypethidine | 2 |
| Ibogaine | 5 |
| Lysergic acid diethylamide (LSD) | 40 |
| Marihuana | 658,000 |
| Mescaline | 25 |
| Methaqualone | 10 |
| Methcathinone | 25 |
| Methyldesorphine | 5 |
| Methyldihydromorphine | 2 |
| Morphine methylbromide | 5 |
| Morphine methylsulfonate | 5 |
| Morphine- N -oxide | 350 |
| N -(1-Adamantyl)-1-pentyl-1 H -indazole-3-carboxamide (AKB48) | 25 |
| N -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 H -indazole-3-carboxamide (ADB-PINACA) | 50 |
| N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide (AB-FUBINACA) | 50 |
| N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 H -indazole-3-carboxamide (AB-CHMINACA) | 15 |
| N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1 H -indazole-3-carboxamide (AB-PINACA) | 15 |
| N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl) | 100 |
| N,N -Dimethylamphetamine | 25 |
| Naphthylpyrovalerone (naphyrone) | 25 |
| N -Benzylpiperazine | 25 |
| N -Ethyl-1-phenylcyclohexylamine | 5 |
| N -Ethylamphetamine | 24 |
| N -Hydroxy-3,4-methylenedioxyamphetamine | 24 |
| Noracymethadol | 2 |
| Norlevorphanol | 52 |
| Normethadone | 2 |
| Normorphine | 40 |
| Para-fluorofentanyl | 5 |
| Parahexyl | 5 |
| Phenomorphan | 2 |
| Pholcodine | 5 |
| Psilocybin | 30 |
| Psilocyn | 50 |
| Quinolin-8-yl 1-(5-fluoropentyl)-1 H -indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) | 50 |
| Quinolin-8-yl 1-pentyl-1 H -indole-3-carboxylate (PB-22; QUPIC) | 50 |
| Tetrahydrocannabinols | 511,250 |
| Thiofentanyl | 2 |
| Tilidine | 25 |
| Trimeperidine | 2 |
| Schedule II | |
| 1-Phenylcyclohexylamine | 5 |
| 1-Piperidinocyclohexanecarbonitrile | 5 |
| 4-Anilino- N -phenethyl-4-piperidine (ANPP) | 2,950,000 |
| Alfentanil | 17,750 |
| Alphaprodine | 3 |
| Amobarbital | 25,125 |
| Amphetamine (for conversion) | 15,000,000 |
| Amphetamine (for sale) | 39,705,000 |
| Carfentanil | 19 |
| Cocaine | 200,000 |
| Codeine (for conversion) | 50,000,000 |
| Codeine (for sale) | 63,900,000 |
| Dextropropoxyphene | 45 |
| Dihydrocodeine | 226,375 |
| Dihydroetorphine | 3 |
| Diphenoxylate (for conversion) | 31,250 |
| Diphenoxylate (for sale) | 1,337,500 |
| Ecgonine | 125,000 |
| Ethylmorphine | 3 |
| Etorphine hydrochloride | 3 |
| Fentanyl | 2,300,000 |
| Glutethimide | 3 |
| Hydrocodone (for conversion) | 235,000 |
| Hydrocodone (for sale) | 88,500,000 |
| Hydromorphone | 8,250,000 |
| Isomethadone | 5 |
| Levo-alphacetylmethadol (LAAM) | 4 |
| Levomethorphan | 30 |
| Levorphanol | 7,125 |
| Lisdexamfetamine | 29,750,000 |
| Meperidine | 5,450,000 |
| Meperidine Intermediate-A | 6 |
| Meperidine Intermediate-B | 11 |
| Meperidine Intermediate-C | 6 |
| Metazocine | 19 |
| Methadone (for sale) | 31,875,000 |
| Methadone Intermediate | 34,375,000 |
| Methamphetamine | 2,061,375 |
| [1,250,000 grams of levo -desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)] | |
| Methylphenidate | 96,750,000 |
| Morphine (for conversion) | 91,250,000 |
| Morphine (for sale) | 62,500,000 |
| Nabilone | 18,750 |
| Noroxymorphone (for conversion) | 17,500,000 |
| Noroxymorphone (for sale) | 1,475,000 |
| Opium (powder) | 112,500 |
| Opium (tincture) | 687,500 |
| Oripavine | 30,000,000 |
| Oxycodone (for conversion) | 6,250,000 |
| Oxycodone (for sale) | 139,150,000 |
| Oxymorphone (for conversion) | 29,000,000 |
| Oxymorphone (for sale) | 7,750,000 |
| Pentobarbital | 38,125,000 |
| Phenazocine | 6 |
| Phencyclidine | 50 |
| Phenmetrazine | 3 |
| Phenylacetone | 50 |
| Racemethorphan | 3 |
| Racemorphan | 3 |
| Remifentanil | 3,750 |
| Secobarbital | 215,003 |
| Sufentanil | 6,255 |
| Tapentadol | 25,500,000 |
| Thebaine | 125,000,000 |
| List I Chemicals | |
| Ephedrine (for conversion) | 100,000 |
| Ephedrine (for sale) | 4,000,000 |
| Phenylpropanolamine (for conversion) | 22,400,000 |
| Phenylpropanolamine (for sale) | 8,500,000 |
| Pseudoephedrine (for conversion) | 7,000 |
| Pseudoephedrine (for sale) | 224,500,000 |
The Administrator also establishes aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Administrator may adjust the 2016 aggregate production quotas and assessment of annual needs as needed.
Dated: September 30, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015-25373 Filed 10-5-15; 8:45 am]
BILLING CODE 4410-09-P